MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD Post published:January 20, 2021 Post category:Press Release
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience Post published:January 14, 2021 Post category:Press Release
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers Post published:January 12, 2021 Post category:Press Release
MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand Post published:January 7, 2021 Post category:Press Release
MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing Post published:January 4, 2021 Post category:Press Release
MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing Post published:December 21, 2020 Post category:Press Release
MindMed Upsizes Previously Announced Bought Deal Public Offering Post published:December 15, 2020 Post category:Press Release
MindMed Announces $50 Million Bought Deal Public Offering Post published:December 15, 2020 Post category:Press Release
MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy Post published:December 14, 2020 Post category:Press Release
MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m) Post published:December 11, 2020 Post category:Press Release